Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Swine Respiratory Diseases Treatment Market Outlook (2022 to 2032)

[276 Pages Report] The global swine respiratory diseases treatment market size is expected to reach a valuation of US$ 2.0 Billion by the end of 2022, and further expand at a CAGR of 6.3% from 2022 to 2032. The market is likely to reach a valuation of US$ 3.6 Billion by the end of 2032. Mycoplasma under the causative agent segment is leading the swine respiratory diseases treatment market and it held a share of about 35.2% in 2021.

Based on the severity and duration of the observable condition, swine respiratory disorders can be grouped into two main categories: those that affect a significant number of pigs and may be hazardous but only last a short while, and those that affect a large number of pigs for an extended period of time. Costs of diseases in the first category are limited rather than continuing.

Swine influenza, classical swine fever, pneumonic pseudorabies, porcine circovirus-associated illness, and pig reproductive and respiratory syndrome (PRRS) are categorized among them. Although pathogenic viruses may survive in a herd, outbreaks of overt sickness are usually self-limiting. Mycoplasma pneumonia and pleuropneumonia are the most common syndromes in the second category like rhinitis atrophic.

Attributes Key Statistics
Global Swine Respiratory Diseases Treatment Market Estimated Size (2022E) US$ 1,978.1 Million
Projected Market Valuation (2032F) US$ 3,649.5 Million
Value-based CAGR (2022 to 2032) 6.3%
Collective Value Share: Top 5 Countries 61.4%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2012 to 2021 Global Swine Respiratory Diseases Treatment Demand Outlook Compared to 2022 to 2032 Forecast

The global swine respiratory diseases treatment market held approximately 1.9% of the overall veterinary services market, which was worth ~US$ 99.5 Billion in 2021. Sales of swine respiratory disease treatment services expanded at a CAGR of 6.1% from 2012 to 2021.

Demand for swine respiratory disease treatment options is on the rise due to the increasing number of foodborne and zoonotic diseases. According to the most recent annual report on food diseases issued by the European Food Safety Authority (EFSA) and the European Center for Disease Prevention and Control (ECDC) in February 2021, foodborne infections are on the rise compared to the previous year, with pathogenic bacteria such as campylobacter spp. being the most common cause.

Around 5175 food outbreaks were documented, accounting for 49463 clinical cases, 3859 hospital admissions, and 60 deaths (+50% compared to the previous year). Salmonella, norovirus, escherichia coli, yersinia enterocolitica, cryptosporidium parvum, and campylobacter jejuni were the most common etiological agents found, while the most common causes of infection were eggs & egg products, bakery items, hog meat, processed foods, water, crustaceans, and vegetables.

Additionally, the market for swine respiratory diseases treatment is anticipated to grow in terms of research & development (R&D) spending and revenue owing to external partnerships and strategic alliances between industries and academia. For instance, in September 2022, Zoetis acquired NewMetrica, which had developed cutting-edge digital instruments in the form of standardized questionnaires that were intended to evaluate health-related quality of life (HRQL) in nonverbal species, as a strategic addition to their companion animal portfolio. Thus, owing to the aforementioned factors, the global swine respiratory diseases treatment market is expected to grow at a CAGR of 6.3% during the forecast period from 2022 to 2032.

Swine Respiratory Diseases Treatment Market

Top Trend Pushing Sales of Swine Respiratory Diseases Treatment Options

  • Government Investments to Boost Access to Advanced Treatment Will Aid Growth

The market is likely to provide an opportunistic perspective owing to various initiatives by governments in emerging countries. Government bodies are investing significantly in healthcare infrastructure modernization, which is expected to bolster access to advanced healthcare services. This factor is set to fuel demand for upgraded technologies, thereby creating an appealing opportunity in the global swine respiratory diseases treatment market.

In high-income economies like the UK and the USA, there will likely be a greater emphasis on innovation to prevent zoonotic diseases combined with biotechnology breakthroughs, which will create a favorable environment for the development of veterinary therapeutics. These methods include systems biology, synthetic biology, and next-generation sequencing among others. Additionally, maintaining investments in multidisciplinary research may accelerate the time to market for new products and enhance the efficiency of therapy development.

The large market potential for veterinary therapeutics is expected to emerge throughout the forecast period as a result of growing economies in emerging markets like Latin America and Asia Pacific. The potential that these markets present are due to a large number of factors, including the increasing cost of living for the urban middle-class population in these regions, which further surges per-capita meat consumption and fuels the need for more effective livestock farming.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Which Factors Are Restraining the Demand for Swine Respiratory Diseases Treatment Options?

Stringent regulations put forward by the USA Food & Drug Administration (FDA) to limit the use of antibiotics for farm animals and the rising cost of innovation-dampening Research and Development investments can hamper the market in the forecast period. If antibiotics are administered to livestock that is raised for food such as swine and other animals, they may lose their efficacy in humans. Antibiotic-resistant bacteria known as superbugs are on the rise as a result of the widespread use of antibiotics in both humans and animals.

The cost of drug innovation has been increasing, as compared to earlier years. The trend is similar for animal healthcare. This is primarily attributed to a limited scope of research for newer diseases in livestock animals. Due to this, drug makers are investing more in the development of innovative drugs for diseases, which are already highly mature. This further raises Research and Development spending and dampens return on investment (ROI). These factors cumulatively propose a negative effect on developmental growth in the swine respiratory diseases treatment market.

Country-wise Insights

What Makes the USA a Large Hub for Swine Respiratory Diseases Treatment Producers?

Rising Prevalence of Zoonotic Diseases in the USA to Push Growth by 2032

The USA dominates the North American swine respiratory diseases treatment market and held a total share of about 52.9% in 2021. It is expected to continue to experience the same growth rate throughout the forecast period.

Owing to the increased swine respiratory diseases related deaths, high consumption of animal meats, and growing prevalence of zoonotic diseases, producers or manufacturers operating in the market are presented with new growth opportunities to develop unique preventive measures, which would further boost the market in the USA

What Makes Canada a Highly Lucrative Industry for Swine Respiratory Diseases Treatment?

Surging Need for H1N1 Influenza Treatment in Canada to Drive the Industry Forward

Canada held approximately 47.1% of the share in the North American swine respiratory diseases treatment market in 2021 and it is expected to showcase growth at a lucrative CAGR of 6.7% during the forecast period.

Influenza viruses are frequently found in pigs, who can be infected by humans, birds, or other pigs. Predominant influenza subtypes prevalent in pigs in Canada are H1N1, H1N2, and H3N2. Swine influenza viruses do not generally infect humans; however, these viruses have occasionally infected humans.

Cases mainly emerge because of direct or indirect contact with pigs in numerous settings such as farms or agricultural fairs. The Canadian Food Inspection Agency (CFIA) advises veterinarians and producers to maintain strict biosecurity measures to reduce any hazards to human or animal health.

What is the Outlook of Germany in the Swine Respiratory Diseases Treatment Industry?

Rising Cases of Swine Fever in Pigs to Propel Growth in Germany by 2032

Germany is set to exhibit a CAGR of nearly 5.8% in the Europe swine respiratory diseases treatment market during the forecast period. Germany is becoming increasingly popular when it comes to health and innovation. With the surging prevalence of influenza A (H1), as well as increasing surveillance and management measures of the disease implemented by the World Health Organization (WHO), the demand for swine respiratory disease treatment options will grow at a rapid pace.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Which is the Highly Preferred Causative Agent in the Swine Respiratory Diseases Industry?

Mycoplasma-based Swine Diseases to Exhibit High Growth in the Upcoming Decade

Mycoplasma-based causative agents are expected to witness high growth at a CAGR of 6.1% by the end of the forecast period. The segment held a swine respiratory diseases treatment market share of about 35.2% in 2021. The major pathogen of enzootic pneumonia, a chronic respiratory disease in pigs, is mycoplasma hyopneumoniae. Infections caused by mycoplasma hyopneumoniae are common in practically all swine production locations, which leads to huge economic losses due to increased medicine consumption and lower pig performance.

Which is the Most Common Type of Swine Respiratory Diseases Treatment Worldwide?

Common Swine Diseases Are Expected to Be Treated with Antibiotics

The drugs segment is expected to create high growth at a CAGR of 6.1% by the end of the forecast period. The segment held a swine respiratory diseases treatment market share of about 63.8% in 2021. Antibiotic use during all stages of growth enhances the efficiency and efficacy of body weight gain, lowers death rates & comorbidities, reduces subclinical disease, and improves pig health.

Which Route of Administration is Gaining Immense Popularity Globally?

Veterans Prefer Oral Route of Administration to Treat Swine Fever Disease

The oral route of administration is expected to exhibit high growth at a CAGR of 6.3% by the end of the forecast period. The segment held a swine respiratory diseases treatment market share of about 86.3% in 2021. The oral route of administration is the most common form of medication administration in farm animals. Medications are mixed with animal feed for ease of ingestion, which would push the segment.

Which is the Most Preferred Distribution Channel across the Globe?

Veterinary Hospitals to Offer Advanced Treatment Options for Swine Bacterial Diseases

Veterinary hospitals held the highest swine respiratory diseases treatment market share of 37.0% in 2021. Pigs are considered to be better medical research subjects than mice as their size, physiology, and genetic makeup are more similar to humans.

Competitive Landscape

With several competitors in the swine respiratory diseases treatment market, the overall industry is highly fragmented. To meet rising consumer demand and expand their customer base, these companies are implementing various methods such as mergers & acquisitions, partnerships & collaborations, and new product launches.

Some of the recent developments in the swine respiratory diseases treatment market are given below:

  • Merck Animal Health, also known as MSD Animal Health outside of the USA and Canada, declared in March 2022 that AROVYNTM (tulathromycin injection) and NUFLOR-S (florfenicol injectable solution), two broad-spectrum, prescription antibiotics used to treat the primary pathogens linked to swine respiratory disease (SRD), had been approved by the USA Food and Drug Administration (FDA).
  • In September 2021, Invetx and Boehringer Ingelheim announced a collaboration to discover, develop, and commercialize innovative veterinary medications.

Scope of the Swine Respiratory Diseases Treatment Market Report

Attribute Details
Estimated Market Size (2022) US$ 1,978.1 Million
Projected Market Valuation (2032) US$ 3,649.5 Million
Value-based CAGR (2022 to 2032) 6.3%
Forecast Period 2012 to 2021
Historical Data Available for 2022 to 2032
Market Analysis Value (US$ Million)
Key Regions Covered North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa
Key Countries Covered USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, North Africa, and South Africa
Key Market Segments Covered Causative Agent, Treatment, Route of Administration, Distribution Channel, and Region
Key Companies Profiled
  • Zoetis
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Elanco Animal Health (Sub. Eli Lilly)
  • Virbac
  • Norbrook
  • Ceva Santé Animale
  • Intervet Inc., (Sub. Merck & Co. Inc.)
  • Vetoquinol SA
  • Bimeda Inc.
  • Kyoritsu Seiyaku Corporation
  • HIPRA
  • Agrilabs, Inc.
  • Ashish LifeSciences Ltd.
  • Cipla Pharmaceuticals.
  • Thermo Fisher Scientific Inc.
  • Huvepharma
Report Coverage Market Forecast, Company Share Analysis, Competition Intelligence, Drivers, Restraints, Opportunities and Threats Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives

Key Segments Covered in Swine Respiratory Diseases Treatment Market Report

By Causative Agent:

  • Virus
  • Mycoplasma
  • Bacteria
  • Others

By Treatment:

  • Drugs
    • Antibiotics
    • Others
  • Vaccines

By Route of Administration:

  • Oral
  • Parenteral

By Distribution Channel:

  • Veterinary Hospitals
  • Veterinary Clinics
  • Pharmacies
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

How much was the swine respiratory diseases treatment market worth in 2021?

The global swine respiratory diseases treatment market was worth US$ 1,852.0 Million in 2021 and is set to expand 1.8x over the next ten years.

What is the sales forecast for the swine respiratory diseases treatment market through 2032?

The swine respiratory diseases treatment market is expected to reach US$ 3,649.5 Million by the end of 2032, with sales revenue set to register a 6.3% CAGR.

What are the key trends shaping the swine respiratory diseases treatment market?

Emergence of biologics & specialty care, growing awareness & affordability of therapeutics for livestock, and shifting distribution of drugs from traditional channels are some of the key trends in the swine respiratory diseases treatment market.

Which are the top five countries driving the swine respiratory disease treatment market?

The USA, Canada, China, the Philippines, and South Korea are expected to drive demand in the swine respiratory diseases treatment market.

What is the North America swine respiratory disease treatment market outlook?

North America is one of the key regions, with the USA accounting for about 52.9% of the region’s swine respiratory diseases treatment market in the year 2021.

At what percentage is the swine respiratory disease treatment market expected to grow in Japan?

The swine respiratory disease treatment market in Japan is expected to register growth at a CAGR of 5.2% over the next ten years.

At what rate is the swine respiratory disease treatment market expected to grow in Germany?

The swine respiratory disease treatment market in Germany is expected to register growth at a CAGR of 5.8% over the next ten years.

Which countries are the key producers of swine respiratory disease treatment products?

China, the USA, and the Philippines are the key producers of swine respiratory diseases treatment

Who are the key players in the swine respiratory diseases treatment market?

Zoetis, Bayer AG, Boehringer Ingelheim GmbH, Elanco Animal Health (Sub. Eli Lilly), Virbac, Norbrook, Ceva Santé Animale, Intervet Inc. (Sub. Merck & Co. Inc.), Vetoquinol SA, Bimeda, Inc., Kyoritsu Seiyaku Corporation, HIPRA, Agrilabs, Inc., Ashish LifeSciences Ltd., Cipla Pharmaceuticals., Thermo Fisher Scientific Inc., and Huvepharma, are some of the key players in the swine respiratory diseases treatment market.

At what rate is the swine respiratory disease treatment market expected to grow in South Korea?

The global swine respiratory disease treatment market in South Korea is expected to register growth at a CAGR of 6.1% over the next ten years.

Table of Content

1. Executive Summary | Swine Respiratory Diseases Treatment Market

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Key Success Factors

    4.1. Disease Epidemiology

    4.2. Key Promotional Strategies - by Manufacturers

    4.3. Regulatory Scenario

    4.4. Reimbursement Scenario

    4.5. Porter’s Analysis

    4.6. PESTLE Analysis

    4.7. Value Chain Analysis

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Global Healthcare Outlook

        5.1.3. Global Veterinary Services Market Outlook

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. New Product Launches

        5.2.2. Rise in Consumption of Pork

        5.2.3. Increasing Requirement of Quality of Life in Animal Healthcare

        5.2.4. Increasing Research and Development Activities

        5.2.5. Adoption of Veterinary Vaccination

        5.2.6. Introduction of Novel and Advanced Technologies

        5.2.7. Government Investments in Veterinary Diseases

        5.2.8. Increasing Prevalence of Porcine Reproductive and Respiratory Syndrome

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

    6.1. COVID-19 and Impact Analysis

        6.1.1. By Causative Agent

        6.1.2. By Treatment

        6.1.3. By Route of Administration

        6.1.4. By Distribution Channel

        6.1.5. By Country

    6.2. 2021 Market Scenario

7. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032

    7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021

    7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Causative Agent

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Million) Analysis and Forecast By Causative Agent, 2012 to 2021

    8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Causative Agent, 2022 to 2032

        8.3.1. Virus

        8.3.2. Mycoplasma

        8.3.3. Bacteria

        8.3.4. Others

    8.4. Market Attractiveness Analysis By Causative Agent

9. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Treatment

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Million) Analysis By Treatment, 2012 to 2021

    9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Treatment, 2022 to 2032

        9.3.1. Drugs

            9.3.1.1. Antibiotics

            9.3.1.2. Others

        9.3.2. Vaccines

    9.4. Market Attractiveness Analysis By Treatment

10. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Route of Administration

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Million) Analysis, By Route of Administration, 2012 to 2021

    10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2022 to 2032

        10.3.1. Oral

        10.3.2. Parenteral

    10.4. Market Attractiveness Analysis By Route of Administration

11. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Million) Analysis, By Distribution Channel, 2012 to 2021

    11.3. Current and Future Market Size (US$ Million) Analysis Forecast By Distribution Channel, 2022 to 2032

        11.3.1. Veterinary Hospitals

        11.3.2. Veterinary Clinics

        11.3.3. Pharmacies

        11.3.4. Others

    11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region

    12.1. Introduction

    12.2. Historical Market Size (US$ Million) Analysis By Region, 2012 to 2021

    12.3. Current Market Size (US$ Million) Analysis and Forecast By Region, 2022 to 2032

        12.3.1. North America

        12.3.2. Latin America

        12.3.3. Europe

        12.3.4. East Asia

        12.3.5. South Asia

        12.3.6. Oceania

        12.3.7. Middle East and Africa (MEA)

    12.4. Market Attractiveness Analysis By Region

13. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032

    13.1. Introduction

    13.2. Pricing Analysis

    13.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021

    13.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032

        13.4.1. By Country

            13.4.1.1. United States of America

            13.4.1.2. Canada

        13.4.2. By Causative Agent

        13.4.3. By Treatment

        13.4.4. By Route of Administration

        13.4.5. By Distribution Channel

    13.5. Market Attractiveness Analysis

        13.5.1. By Country

        13.5.2. By Causative Agent

        13.5.3. By Treatment

        13.5.4. By Route of Administration

        13.5.5. By Distribution Channel

    13.6. Market Trends

    13.7. Key Market Participants - Intensity Mapping

    13.8. Drivers and Restraints - Impact Analysis

    13.9. Country-Level Analysis & Forecast

        13.9.1. USA Market Analysis

            13.9.1.1. .Introduction

            13.9.1.2. Market Analysis and Forecast by Market Taxonomy

                13.9.1.2.1. By Causative Agent

                13.9.1.2.2. By Treatment

                13.9.1.2.3. By Route of Administration

                13.9.1.2.4. By Distribution Channel

        13.9.2. Canada Market Analysis

            13.9.2.1. Introduction

            13.9.2.2. Market Analysis and Forecast by Market Taxonomy

                13.9.2.2.1. By Causative Agent

                13.9.2.2.2. By Treatment

                13.9.2.2.3. By Route of Administration

                13.9.2.2.4. By Distribution Channel

14. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032

    14.1. Introduction

    14.2. Pricing Analysis

    14.3. Historical Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2012 to 2021

    14.4. Current and Future Market Size (US$ Million) Analysis Forecast By Market Taxonomy, 2022 to 2032

        14.4.1. By Country

            14.4.1.1. Mexico

            14.4.1.2. Brazil

            14.4.1.3. Argentina

            14.4.1.4. Rest of Latin America

        14.4.2. By Causative Agent

        14.4.3. By Treatment

        14.4.4. By Route of Administration

        14.4.5. By Distribution Channel

    14.5. Market Attractiveness Analysis

        14.5.1. By Country

        14.5.2. By Causative Agent

        14.5.3. By Treatment

        14.5.4. By Route of Administration

        14.5.5. By Distribution Channel

    14.6. Market Trends

    14.7. Key Market Participants - Intensity Mapping

    14.8. Drivers and Restraints - Impact Analysis

    14.9. Country-Level Analysis & Forecast

        14.9.1. Mexico Market Analysis

            14.9.1.1. Introduction

            14.9.1.2. Market Analysis and Forecast by Market Taxonomy

                14.9.1.2.1. By Causative Agent

                14.9.1.2.2. By Treatment

                14.9.1.2.3. By Route of Administration

                14.9.1.2.4. By Distribution Channel

        14.9.2. Brazil Market Analysis

            14.9.2.1. Introduction

            14.9.2.2. Market Analysis and Forecast by Market Taxonomy

                14.9.2.2.1. By Causative Agent

                14.9.2.2.2. By Treatment

                14.9.2.2.3. By Route of Administration

                14.9.2.2.4. By Distribution Channel

        14.9.3. Argentina Market Analysis

            14.9.3.1. Introduction

            14.9.3.2. Market Analysis and Forecast by Market Taxonomy

                14.9.3.2.1. By Causative Agent

                14.9.3.2.2. By Treatment

                14.9.3.2.3. By Route of Administration

                14.9.3.2.4. By Distribution Channel

15. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032

    15.1. Introduction

    15.2. Pricing Analysis

    15.3. Historical Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2012 to 2021

    15.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032

        15.4.1. By Country

            15.4.1.1. Germany

            15.4.1.2. Italy

            15.4.1.3. France

            15.4.1.4. United Kingdom

            15.4.1.5. Spain

            15.4.1.6. BENELUX

            15.4.1.7. Russia

            15.4.1.8. Nordic Countries

            15.4.1.9. Rest of Europe

        15.4.2. By Causative Agent

        15.4.3. By Treatment

        15.4.4. By Route of Administration

        15.4.5. By Distribution Channel

    15.5. Market Attractiveness Analysis

        15.5.1. By Country

        15.5.2. By Causative Agent

        15.5.3. By Treatment

        15.5.4. By Route of Administration

        15.5.5. By Distribution Channel

    15.6. Market Trends

    15.7. Key Market Participants - Intensity Mapping

    15.8. Drivers and Restraints - Impact Analysis

    15.9. Country-Level Analysis & Forecast

        15.9.1. Germany Market Analysis

            15.9.1.1. Introduction

            15.9.1.2. Market Analysis and Forecast by Market Taxonomy

                15.9.1.2.1. By Causative Agent

                15.9.1.2.2. By Treatment

                15.9.1.2.3. By Route of Administration

                15.9.1.2.4. By Distribution Channel

        15.9.2. Italy Market Analysis

            15.9.2.1. Introduction

            15.9.2.2. Market Analysis and Forecast by Market Taxonomy

                15.9.2.2.1. By Causative Agent

                15.9.2.2.2. By Treatment

                15.9.2.2.3. By Route of Administration

                15.9.2.2.4. By Distribution Channel

        15.9.3. France Market Analysis

            15.9.3.1. Introduction

            15.9.3.2. Market Analysis and Forecast by Market Taxonomy

                15.9.3.2.1. By Causative Agent

                15.9.3.2.2. By Treatment

                15.9.3.2.3. By Route of Administration

                15.9.3.2.4. By Distribution Channel

        15.9.4. UK Market Analysis

            15.9.4.1. Introduction

            15.9.4.2. Market Analysis and Forecast by Market Taxonomy

                15.9.4.2.1. By Causative Agent

                15.9.4.2.2. By Treatment

                15.9.4.2.3. By Route of Administration

                15.9.4.2.4. By Distribution Channel

        15.9.5. Spain Market Analysis

            15.9.5.1. Introduction

            15.9.5.2. Market Analysis and Forecast by Market Taxonomy

                15.9.5.2.1. By Causative Agent

                15.9.5.2.2. By Treatment

                15.9.5.2.3. By Route of Administration

                15.9.5.2.4. By Distribution Channel

        15.9.6. BENELUX Market Analysis

            15.9.6.1. Introduction

            15.9.6.2. Market Analysis and Forecast by Market Taxonomy

                15.9.6.2.1. By Causative Agent

                15.9.6.2.2. By Treatment

                15.9.6.2.3. By Route of Administration

                15.9.6.2.4. By Distribution Channel

        15.9.7. Russia Market Analysis

            15.9.7.1. Introduction

            15.9.7.2. Market Analysis and Forecast by Market Taxonomy

                15.9.7.2.1. By Causative Agent

                15.9.7.2.2. By Treatment

                15.9.7.2.3. By Route of Administration

                15.9.7.2.4. By Distribution Channel

        15.9.8. Nordic Countries Market Analysis

            15.9.8.1. Introduction

            15.9.8.2. Market Analysis and Forecast by Market Taxonomy

                15.9.8.2.1. By Causative Agent

                15.9.8.2.2. By Treatment

                15.9.8.2.3. By Route of Administration

                15.9.8.2.4. By Distribution Channel

16. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032

    16.1. Introduction

    16.2. Pricing Analysis

    16.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021

    16.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032

        16.4.1. By Country

            16.4.1.1. China

            16.4.1.2. Japan

            16.4.1.3. South Korea

        16.4.2. By Causative Agent

        16.4.3. By Treatment

        16.4.4. By Route of Administration

        16.4.5. By Distribution Channel

    16.5. Market Attractiveness Analysis

        16.5.1. By Country

        16.5.2. By Causative Agent

        16.5.3. By Treatment

        16.5.4. By Route of Administration

        16.5.5. By Distribution Channel

    16.6. Market Trends

    16.7. Key Market Participants - Intensity Mapping

    16.8. Drivers and Restraints - Impact Analysis

    16.9. Country-Level Analysis & Forecast

        16.9.1. China Market Analysis

            16.9.1.1. Introduction

            16.9.1.2. Market Analysis and Forecast by Market Taxonomy

                16.9.1.2.1. By Causative Agent

                16.9.1.2.2. By Treatment

                16.9.1.2.3. By Route of Administration

                16.9.1.2.4. By Distribution Channel

        16.9.2. Japan Market Analysis

            16.9.2.1. Introduction

            16.9.2.2. Market Analysis and Forecast by Market Taxonomy

                16.9.2.2.1. By Causative Agent

                16.9.2.2.2. By Treatment

                16.9.2.2.3. By Route of Administration

                16.9.2.2.4. By Distribution Channel

        16.9.3. South Korea Market Analysis

            16.9.3.1. Introduction

            16.9.3.2. Market Analysis and Forecast by Market Taxonomy

                16.9.3.2.1. By Causative Agent

                16.9.3.2.2. By Treatment

                16.9.3.2.3. By Route of Administration

                16.9.3.2.4. By Distribution Channel

17. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032

    17.1. Introduction

    17.2. Pricing Analysis

    17.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021

    17.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032

        17.4.1. By Country

            17.4.1.1. India

            17.4.1.2. Indonesia

            17.4.1.3. Malaysia

            17.4.1.4. Thailand

            17.4.1.5. Rest of South Asia

        17.4.2. By Causative Agent

        17.4.3. By Treatment

        17.4.4. By Route of Administration

        17.4.5. By Distribution Channel

    17.5. Market Attractiveness Analysis

        17.5.1. By Country

        17.5.2. By Causative Agent

        17.5.3. By Treatment

        17.5.4. By Route of Administration

        17.5.5. By Distribution Channel

    17.6. Market Trends

    17.7. Key Market Participants - Intensity Mapping

    17.8. Drivers and Restraints - Impact Analysis

    17.9. Country-Level Analysis & Forecast

        17.9.1. India Market Analysis

            17.9.1.1. Introduction

            17.9.1.2. Market Analysis and Forecast by Market Taxonomy

                17.9.1.2.1. By Causative Agent

                17.9.1.2.2. By Treatment

                17.9.1.2.3. By Route of Administration

                17.9.1.2.4. By Distribution Channel

        17.9.2. Indonesia Market Analysis

            17.9.2.1. Introduction

            17.9.2.2. Market Analysis and Forecast by Market Taxonomy

                17.9.2.2.1. By Causative Agent

                17.9.2.2.2. By Treatment

                17.9.2.2.3. By Route of Administration

                17.9.2.2.4. By Distribution Channel

        17.9.3. Malaysia Market Analysis

            17.9.3.1. Introduction

            17.9.3.2. Market Analysis and Forecast by Market Taxonomy

                17.9.3.2.1. By Causative Agent

                17.9.3.2.2. By Treatment

                17.9.3.2.3. By Route of Administration

                17.9.3.2.4. By Distribution Channel

        17.9.4. Thailand Market Analysis

            17.9.4.1. Introduction

            17.9.4.2. Market Analysis and Forecast by Market Taxonomy

                17.9.4.2.1. By Causative Agent

                17.9.4.2.2. By Treatment

                17.9.4.2.3. By Route of Administration

                17.9.4.2.4. By Distribution Channel

        17.9.5. Rest of South Asia Market Analysis

            17.9.5.1. Introduction

            17.9.5.2. Market Analysis and Forecast by Market Taxonomy

                17.9.5.2.1. By Causative Agent

                17.9.5.2.2. By Treatment

                17.9.5.2.3. By Route of Administration

                17.9.5.2.4. By Distribution Channel

18. Oceania Market 2012 to 2021 and Forecast 2022 to 2032

    18.1. Introduction

    18.2. Pricing Analysis

    18.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021

    18.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032

        18.4.1. By Country

            18.4.1.1. Australia

            18.4.1.2. New Zealand

        18.4.2. By Causative Agent

        18.4.3. By Treatment

        18.4.4. By Route of Administration

        18.4.5. By Distribution Channel

    18.5. Market Attractiveness Analysis

        18.5.1. By Country

        18.5.2. By Causative Agent

        18.5.3. By Treatment

        18.5.4. By Route of Administration

        18.5.5. By Distribution Channel

    18.6. Key Market Participants - Intensity Mapping

    18.7. Drivers and Restraints - Impact Analysis

    18.8. Country-Level Analysis & Forecast

        18.8.1. Australia Market Analysis

            18.8.1.1. Introduction

            18.8.1.2. Market Analysis and Forecast by Market Taxonomy

                18.8.1.2.1. By Causative Agent

                18.8.1.2.2. By Treatment

                18.8.1.2.3. By Route of Administration

                18.8.1.2.4. By Distribution Channel

        18.8.2. New Zealand Market Analysis

            18.8.2.1. Introduction

            18.8.2.2. Market Analysis and Forecast by Market Taxonomy

                18.8.2.2.1. By Causative Agent

                18.8.2.2.2. By Treatment

                18.8.2.2.3. By Route of Administration

                18.8.2.2.4. By Distribution Channel

19. Middle East and Africa (MEA) Market Analysis 2012 to 2021 and Forecast 2022 to 2032

    19.1. Introduction

    19.2. Pricing Analysis

    19.3. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021

    19.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032

        19.4.1. By Country

            19.4.1.1. GCC Countries

            19.4.1.2. Turkey

            19.4.1.3. South Africa

            19.4.1.4. North Africa

            19.4.1.5. Rest of Middle East and Africa

        19.4.2. By Causative Agent

        19.4.3. By Treatment

        19.4.4. By Route of Administration

        19.4.5. By Distribution Channel

    19.5. Market Attractiveness Analysis

        19.5.1. By Country

        19.5.2. By Causative Agent

        19.5.3. By Treatment

        19.5.4. By Route of Administration

        19.5.5. By Distribution Channel

    19.6. Market Trends

    19.7. Key Market Participants - Intensity Mapping

    19.8. Drivers and Restraints - Impact Analysis

    19.9. Country-Level Analysis & Forecast

        19.9.1. GCC Countries Market Analysis

            19.9.1.1. Introduction

            19.9.1.2. Market Analysis and Forecast by Market Taxonomy

                19.9.1.2.1. By Causative Agent

                19.9.1.2.2. By Treatment

                19.9.1.2.3. By Route of Administration

                19.9.1.2.4. By Distribution Channel

        19.9.2. Turkey Market Analysis

            19.9.2.1. Introduction

            19.9.2.2. Market Analysis and Forecast by Market Taxonomy

                19.9.2.2.1. By Causative Agent

                19.9.2.2.2. By Treatment

                19.9.2.2.3. By Route of Administration

                19.9.2.2.4. By Distribution Channel

        19.9.3. South Africa Market Analysis

            19.9.3.1. Introduction

            19.9.3.2. Market Analysis and Forecast by Market Taxonomy

                19.9.3.2.1. By Causative Agent

                19.9.3.2.2. By Treatment

                19.9.3.2.3. By Route of Administration

                19.9.3.2.4. By Distribution Channel

        19.9.4. North Africa Market Analysis

            19.9.4.1. Introduction

            19.9.4.2. Market Analysis and Forecast by Market Taxonomy

                19.9.4.2.1. By Causative Agent

                19.9.4.2.2. By Treatment

                19.9.4.2.3. By Route of Administration

                19.9.4.2.4. By Distribution Channel

20. Market Structure Analysis

    20.1. Market Analysis by Tier of Companies

    20.2. Market Concentration

    20.3. Market Share Analysis of Top Players

    20.4. Market Presence Analysis

        20.4.1. By Regional footprint of Players

        20.4.2. Product foot print by Players

        20.4.3. Channel Foot Print by Players

21. Competition Analysis

    21.1. Competition Dashboard

    21.2. Competition Benchmarking

    21.3. Competition Deep Dive

        21.3.1. Zoetis

            21.3.1.1. Overview

            21.3.1.2. Product Portfolio

            21.3.1.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.1.4. Sales Footprint

            21.3.1.5. Key Financials

            21.3.1.6. SWOT Analysis

            21.3.1.7. Strategy Overview

        21.3.2. Bayer AG

            21.3.2.1. Overview

            21.3.2.2. Product Portfolio

            21.3.2.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.2.4. Sales Footprint

            21.3.2.5. Key Financials

            21.3.2.6. SWOT Analysis

            21.3.2.7. Strategy Overview

        21.3.3. Boehringer Ingelheim GmbH

            21.3.3.1. Overview

            21.3.3.2. Product Portfolio

            21.3.3.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.3.4. Sales Footprint

            21.3.3.5. Key Financials

            21.3.3.6. SWOT Analysis

            21.3.3.7. Strategy Overview

        21.3.4. Elanco Animal Health (Sub. Eli Lilly)

            21.3.4.1. Overview

            21.3.4.2. Product Portfolio

            21.3.4.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.4.4. Sales Footprint

            21.3.4.5. Key Financials

            21.3.4.6. SWOT Analysis

            21.3.4.7. Strategy Overview

        21.3.5. Virbac

            21.3.5.1. Overview

            21.3.5.2. Product Portfolio

            21.3.5.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.5.4. Sales Footprint

            21.3.5.5. Key Financials

            21.3.5.6. SWOT Analysis

            21.3.5.7. Strategy Overview

        21.3.6. Norbrook

            21.3.6.1. Overview

            21.3.6.2. Product Portfolio

            21.3.6.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.6.4. Sales Footprint

            21.3.6.5. Key Financials

            21.3.6.6. SWOT Analysis

            21.3.6.7. Strategy Overview

        21.3.7. Ceva Santé Animale

            21.3.7.1. Overview

            21.3.7.2. Product Portfolio

            21.3.7.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.7.4. Sales Footprint

            21.3.7.5. Key Financials

            21.3.7.6. SWOT Analysis

            21.3.7.7. Strategy Overview

        21.3.8. Intervet Inc., (Sub. Merck & Co. Inc.)

            21.3.8.1. Overview

            21.3.8.2. Product Portfolio

            21.3.8.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.8.4. Sales Footprint

            21.3.8.5. Key Financials

            21.3.8.6. SWOT Analysis

            21.3.8.7. Strategy Overview

        21.3.9. Vetoquinol SA

            21.3.9.1. Overview

            21.3.9.2. Product Portfolio

            21.3.9.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.9.4. Sales Footprint

            21.3.9.5. Key Financials

            21.3.9.6. SWOT Analysis

            21.3.9.7. Strategy Overview

        21.3.10. Bimeda Inc.,

            21.3.10.1. Overview

            21.3.10.2. Product Portfolio

            21.3.10.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.10.4. Sales Footprint

            21.3.10.5. Key Financials

            21.3.10.6. SWOT Analysis

            21.3.10.7. Strategy Overview

        21.3.11. Kyoritsu Seiyaku Corporation

            21.3.11.1. Overview

            21.3.11.2. Product Portfolio

            21.3.11.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.11.4. Sales Footprint

            21.3.11.5. Key Financials

            21.3.11.6. SWOT Analysis

            21.3.11.7. Strategy Overview

        21.3.12. HIPRA

            21.3.12.1. Overview

            21.3.12.2. Product Portfolio

            21.3.12.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.12.4. Sales Footprint

            21.3.12.5. Key Financials

            21.3.12.6. SWOT Analysis

            21.3.12.7. Strategy Overview

        21.3.13. Agrilabs, Inc.,

            21.3.13.1. Overview

            21.3.13.2. Product Portfolio

            21.3.13.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.13.4. Sales Footprint

            21.3.13.5. Key Financials

            21.3.13.6. SWOT Analysis

            21.3.13.7. Strategy Overview

        21.3.14. Ashish Lifesciences Ltd.,

            21.3.14.1. Overview

            21.3.14.2. Product Portfolio

            21.3.14.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.14.4. Sales Footprint

            21.3.14.5. Key Financials

            21.3.14.6. SWOT Analysis

            21.3.14.7. Strategy Overview

        21.3.15. Cipla Pharmaceuticals.

            21.3.15.1. Overview

            21.3.15.2. Product Portfolio

            21.3.15.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.15.4. Sales Footprint

            21.3.15.5. Key Financials

            21.3.15.6. SWOT Analysis

            21.3.15.7. Strategy Overview

        21.3.16. Thermo Fisher Scientific Inc.,

            21.3.16.1. Overview

            21.3.16.2. Product Portfolio

            21.3.16.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.16.4. Sales Footprint

            21.3.16.5. Key Financials

            21.3.16.6. SWOT Analysis

            21.3.16.7. Strategy Overview

        21.3.17. Huvepharma.

            21.3.17.1. Overview

            21.3.17.2. Product Portfolio

            21.3.17.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.17.4. Sales Footprint

            21.3.17.5. Key Financials

            21.3.17.6. SWOT Analysis

            21.3.17.7. Strategy Overview

22. Assumptions and Acronyms Used

23. Research Methodology

Recommendations

Healthcare

Farm Animal Drug Market

Published : May 2024

Healthcare

Animal Healthcare Market

Published : January 2023

Healthcare

Veterinary Vaccines Market

Published : January 2023

Explore Healthcare Insights

View Reports

Swine Respiratory Diseases Treatment Market